Background/Aims: Increasing evidence suggests a link between brain-derived neurotrophic factor (BDNF) and suicidal behaviour (SB). Furthermore, decreased peripheral BDNF levels have been associated with clinical symptoms in various psychiatric disorders as well as with personality dimensions in healthy individuals. However, the relationship between BDNF and psychopathology is poorly investigated regarding SB. Methods: Plasma BDNF concentrations were analysed in 61 recent suicide attempters. Clinical symptoms were evaluated using the Comprehensive Psychopathological Rating Scale. Personality dimensions were assessed using the Marke-Nyman Temperament Scale. Results: Plasma BDNF correlated positively and significantly with the personality dimension Solidity but not with the other personality dimensions or with clinical symptoms. Conclusion: BDNF plays an important role in the regulation of neuroplasticity and neurogenesis in humans. Our results indicate that lower BDNF concentrations are associated with higher levels of impulsiveness and changeability (low scores on the Solidity scale). Furthermore, low plasma BDNF levels may be proposed as a trait marker rather than a state marker for attempted suicide.

1.
Huang EJ, Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
2.
Dwivedi Y: Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med 2010;42:87-96.
3.
Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN: Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003;60:804-815.
4.
Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R: Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005;136:29-37.
5.
Grah M, Mihanovic M, Ruljancic N, Restek-Petrovic B, Molnar S, Jelavic S: Brain-derived neurotrophic factor as a suicide factor in mental disorders. Acta Neuropsychiatr 2014;26:356-363.
6.
Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
7.
Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F: Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45:995-1004.
8.
Nurjono M, Lee J, Chong SA: A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin Psychopharmacol Neurosci 2012;10:61-70.
9.
Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, Lee SW, Yoon D, Han C, Kim DJ, Choi SH: Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:78-85.
10.
Diefenbach GJ, Woolley SB, Goethe JW: The association between self-reported anxiety symptoms and suicidality. J Nerv Ment Dis 2009;197:92-97.
11.
Terracciano A, Martin B, Ansari D, Tanaka T, Ferrucci L, Maudsley S, Mattson MP, Costa PT Jr: Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav 2010;9:512-518.
12.
Lang UE, Hellweg R, Gallinat J: BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004;29:795-798.
13.
Minelli A, Zanardini R, Bonvicini C, Sartori R, Pedrini L, Gennarelli M, Bocchio-Chiavetto L: BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2011;261:323-329.
14.
Yasui-Furukori N, Tsuchimine S, Kaneda A, Sugawara N, Ishioka M, Kaneko S: Association between plasma brain-derived neurotrophic factor levels and personality traits in healthy Japanese subjects. Psychiatry Res 2013;210:220-223.
15.
Terracciano A, Lobina M, Piras MG, Mulas A, Cannas A, Meirelles O, Sutin AR, Zonderman AB, Uda M, Crisponi L, Schlessinger D: Neuroticism, depressive symptoms, and serum BDNF. Psychosom Med 2011;73:638-642.
16.
Okuno K, Yoshimura R, Ueda N, Ikenouchi-Sugita A, Umene-Nakano W, Hori H, Hayashi K, Katsuki A, Chen HI, Nakamura J: Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan. Psychiatry Res 2011;186:326-332.
17.
Brezo J, Paris J, Turecki G: Personality traits as correlates of suicidal ideation, suicide attempts, and suicide completions: a systematic review. Acta Psychiatr Scand 2006;113:180-206.
18.
Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553-1561.
19.
Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP: Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010;13:535-539.
20.
Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S: Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353.
21.
Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4:819-828.
22.
Beck AT, Davis J, Frederick, CJ, Perlin S, Pokorny A, Schulman R, Seiden R, Wittlin B: Classification and nomenclature; in Resnik HPL, Hathorne B (eds): Suicide Prevention in the Seventies. Washington, US Government Printing Office, 1972.
23.
American Psychiatric Association: Diagnostics and Statistical Manual of Mental Disorders, ed 3 rev. Washington, American Psychiatric Association, 1987.
24.
Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G: A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl 1978;271:25-27.
25.
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382-389.
26.
Tyrer P, Owen RT, Cicchetti DV: The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry 1984;47:970-975.
27.
Nyman GE, Marke S: The Differential Psychology of Sjöbring (in Swedish with an English summary). Lund, Gleerups, 1962.
28.
Huang MC, Chen CH, Chen CH, Liu SC, Ho CJ, Shen WW, Leu SJ: Alterations of serum brain-derived neurotrophic factor levels in early alcohol withdrawal. Alcohol Alcohol 2008;43:241-245.
29.
Corominas-Roso M, Roncero C, Eiroa-Orosa FJ, Gonzalvo B, Grau-Lopez L, Ribases M, Rodriguez-Cintas L, Sánchez-Mora C, Ramos-Quiroga JA, Casas M: Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. Eur Neuropsychopharmacol 2013;23:1078-1084.
30.
Huang MC, Chen CH, Liu HC, Chen CC, Ho CC, Leu SJ: Differential patterns of serum brain-derived neurotrophic factor levels in alcoholic patients with and without delirium tremens during acute withdrawal. Alcohol Clin Exp Res 2011;35:126-131.
31.
Ren W, Tao J, Wei Y, Su H, Zhang J, Xie Y, Guo J, Zhang X, Zhang H, He J: Time-dependent serum brain-derived neurotrophic dactor decline during methamphetamine withdrawal. Medicine (Baltimore) 2016;95:e2604.
32.
Rydin E, Asberg M, Edman G, Schalling D: Violent and nonviolent suicide attempts - a controlled Rorschach study. Acta Psychiatr Scand 1990;82:30-39.
33.
Sjöbring H: Personality Structure and Development. Copenhagen, Munksgaard, 1973.
34.
Coppen A: The Marke-Nyman temperament scale: an English translation. Br J Med Psychol 1966;39:55-59.
35.
Eysenck HJ, Eysenck SBG: Manual of the Eysenck Personality Questionnaire. London, Hodder and Stoughton, 1975.
36.
Segraves RT: Intercorrelations between the Sjöbring and Eysenckian personality dimensions. Acta Psychiatr Scand 1971;47:288-294.
37.
Beck AT, Davis J, Frederick, CJ, Perlin S, Pokorny A, Schulman R, Seiden R, Wittlin B: Classification and nomenclature; in Resnik HPL, Hathorne B (eds): Suicide Prevention in the Seventies. Washington, US Government Printing Office, 1972.
38.
Schalling D, Asberg M: Biological and psychological correlates of impulsiveness and monotony avoidance; in Strelau J, Farley FH, Gale A (eds): The Biological Bases of Personality and Behavior: Theories, Measurement Techniques, and Development. Washington, Hemisphere, 1985, vol 1, pp 181-194.
39.
Gvion Y, Apter A: Aggression, impulsivity, and suicide behavior: a review of the literature. Arch Suicide Res 2011;15:93-112.
40.
Zörner B, Wolfer DP, Brandis D, Kretz O, Zacher C, Madani R, Grunwald I, Lipp HP, Klein R, Henn FA, Gass P: Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than ‘depressive'. Biol Psychiatry 2003;54:972-982.
41.
Kim H, Heo HI, Kim DH, Ko IG, Lee SS, Kim SE, Kim BK, Kim TW, Ji ES, Kim JD, Shin MS, Choi YW, Kim CJ: Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats. Neurosci Lett 2011;504:35-39.
42.
Duclot F, Kabbaj M: Individual differences in novelty seeking predict subsequent vulnerability to social defeat through a differential epigenetic regulation of brain-derived neurotrophic factor expression. J Neurosci 2013;33:11048-11060.
43.
Lee BH, Kim H, Park SH, Kim YK: Decreased plasma BDNF level in depressive patients. J Affect Disord 2007;101:239-244.
44.
Zhang J, Zhang X, Su H, Tao J, Xie Y, Han B, Lu Y, Wei Y, Sun H, Wang Y, Wu W, Zou S, Liang H, Zoghbi AW, Tang W, He J: Increased serum brain-derived neurotrophic factor levels during opiate withdrawal. Neurosci Lett 2014;571:6.
45.
Bhang SY, Kim K, Choi SW, Ahn JH: Do levels of brain-derived neurotrophic factor (BDNF) in plasma correlate with psychopathology in healthy subjects? Neurosci Lett 2012;512:72-77.
46.
Huang T, Larsen KT, Ried-Larsen M, Møller NC, Andersen LB: The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: a review. Scand J Med Sci Sports 2014;24:1-10.
47.
Pluchino N, Cubeddu A, Begliuomini S, Merlini S, Giannini A, Bucci F, Casarosa E, Luisi M, Cela V, Genazzani AR: Daily variation of brain-derived neurotrophic factor and cortisol in women with normal menstrual cycles, undergoing oral contraception and in postmenopause. Hum Reprod 2009;24:2303-2309.
48.
Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lèvi AC, Tabrizi SJ, Di Donato S, Cattaneo E: Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One 2011;6:e22966.
49.
Begliuomini S, Lenzi E, Ninni F, Casarosa E, Merlini S, Pluchino N, Valentino V, Luisi S, Luisi M, Genazzani AR: Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol 2008;197:429-435.
50.
Dalley JW, Roiser JP: Dopamine, serotonin and impulsivity. Neuroscience 2012;215:42-58.
51.
Ryding E, Ahnlide JA, Lindström M, Rosén I, Träskman-Bendz L: Regional brain serotonin and dopamine transporter binding capacity in suicide attempters relate to impulsiveness and mental energy. Psychiatry Res 2006;148:195-203.
52.
Homberg JR: The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev 2014;43:35-47.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.